Mr. Curnock Cook has served as a member of the Company’s board of directors since July 1995 and as Chairman of the board of directors since February 1998. Mr. Curnock Cook has also served as Chairman of International Bioscience Managers Limited, a corporate and investment advisory firm since 2000, and currently serves as Managing Director of Bioscience Managers pty Ltd, a medical sciences fund manager. From 1987 to 2000, Mr. Curnock Cook was a Director of Rothschild Asset Management Limited, a corporate and investment advisory company, and was responsible for the Rothschild Bioscience Unit. Mr. Curnock Cook founded the International Biochemicals Group in 1975, which was sold to Royal Dutch Shell in 1985, where he served as managing director until 1987 He also serves as a member of the boards of Avita Medical Ltd, Adherium Ltd, SeaDragon Ltd. Mr. Curnock Cook holds an M.A. in natural sciences from Trinity College, Dublin.
Mr. Drapeau has served as a member of the Company’s board of directors since March 2011. Since October 2007 through February 2016, Mr. Drapeau has served in various management positions at InSite Vision, a traded ophthalmology drug development company that was acquired in October 2015. From November 2008 until December 2010, these positions included Vice President, CFO and CEO of InSite Vision. Prior to InSite Vision, he served as CFO, Senior Vice President, Finance, at Nektar Therapeutics, a biopharmaceutical company, from January 2006 to August 2007. From August 2004 until May 2005, he served as acting CEO and as Senior Vice President and CFO from August 2002 to August 2005 for BioMarin Pharmaceutical Inc. Previously, Mr. Drapeau spent 30 years at Arthur Andersen including 19 years as an Audit Partner in Arthur Andersen’s Northern California Audit and Business Consulting practice which included 12 years as Managing Partner. He also serves as a member of the board of Bio-Rad Laboratories and InterMune, Inc. Mr. Drapeau received both his undergraduate degree in Mechanical Engineering and an M.B.A. from Stanford University.
Dr. Grint has served as a member of the Company’s board of directors since November 2015. Prior to becoming CEO of AmpliPhi, Dr. Grint was the President and CEO of Regulus Therapeutics, Inc., a company focused on the discovery and development of microRNA therapeutics, since June 2015. Dr. Grint has more than two decades of experience in biologics and small molecule development, including the successful commercialization of products in oncology, anti-infectives and immunology. Prior to his role at Regulus, he served as President of Cerexa, Inc. Dr. Grint has also served in senior management roles at Forest Research Institute, Kalypsys, Zephyr Sciences, Pfizer, IDEC Pharmaceuticals and Schering-Plough Corporation. He is a Fellow of the Royal College of Pathologists, and is a member of numerous professional and medical societies. He holds a degree from St. Mary’s College, University of London and a medical degree from St. Bartholomew’s Hospital College, University of London.
Ms. Johnson has served as a member of the Company’s board of directors since May 2014, and served as interim COO from September 2014 to January 2017. From 2005 to January 2014 Ms. Johnson served as a Venture Partner at ProQuest Investments, a venture capital firm. From November 2006 until January 2014, Ms. Johnson served as the President and Chief Executive Officer of Aires Pharmaceuticals, a ProQuest portfolio company. Prior to joining ProQuest, she served as Senior Vice President, Corporate Development, at Salmedix Inc., and has held senior business and corporate development positions at WomenFirst Healthcare, Prizm Pharmaceuticals (Selective Genetics Inc.), Cytel Corp., Synbiotics Corp., and Murex Corp. (Cambridge U.K.). Additionally, Ms. Johnson served as Assistant Director for the Center for Devices and Radiological Health at the U.S. Food and Drug Administration. Ms. Johnson received an M.B.A. from Loyola University, an M.S. in Clinical Microbiology from the Hahnemann Medical School and a B.S. in Microbiology from the University of Maryland.
Dr. Perry has served as a member of Company’s board of directors since November 2005. Since June 2017, Dr. Perry has served as the CEO of Avita Medical. Previously, Dr. Perry served as Senior Vice President and Chief Scientific Officer of Business Development and Licensing for Novartis AG. Prior to joining Novartis in 2012, he was a Venture Partner with Bay City Capital, a venture capital firm beginning in 2005. While serving in this capacity he concurrently served as President and Chief Medical Officer at Poniard Pharmaceuticals, Inc., a publicly held drug development company from 2009 to 2011 and also previously served as Chief Development Officer of VIA Pharmaceuticals, Inc., another publicly held biotechnology company from 2005 to 2009. Dr. Perry has held a variety of additional management and board positions, including Chairman and CEO of Extropy Pharmaceuticals, Inc., a privately held pediatric specialty pharmaceutical company, from 2003 to 2005; President and CEO of Pharsight Corporation, a publicly held software and consulting services firm from 2002 to 2003; global head of research and development for Baxter Healthcare from 2000 to 2002; and from 1997 to 2000 as president and CEO of both SyStemix Inc. and Genetic Therapy Inc., two wholly owned subsidiaries of Novartis Pharma, where he was Vice President of Regulatory Affairs from 1994 to 1997. Prior to 1994, Dr. Perry held various management positions with Syntex Corporation, Schering-Plough Corporation and BioResearch Laboratories, Inc. He also serves as a member of the board of Arrowhead Research Corporation and of Avita Medical Ltd. Dr. Perry holds a Doctor of Veterinary Medicine, a Ph.D. in Biomedical Science – Cardiopulmonary Pharmacology and a B.S. in Physics from the University of Guelph.
Mr. Samant has served as a member of the Company’s board of directors since November 2015. Since November 2000, he has served as President and CEO of Vical, Inc., a developer of biopharmaceutical products for the prevention and treatment of chronic life-threatening infectious diseases. Prior to Vical, Mr. Samant gained more than two decades of U.S. and international sales, marketing, operations and business development experience at Merck & Co, serving as COO of the Merck Vaccine Division, VP of Vaccine Operations, VP of Business Affairs and Executive Director of Materials Management. Mr. Samant has served on the boards of Raptor Pharmaceuticals, BioMarin, Aeras Global TB Vaccine Foundation and the International Vaccine Institute. He also served on the Board of Trustees of The National Foundation for Infectious Diseases. He holds a Bachelor’s degree in Chemical Engineering from the University of Bombay, a Master’s degree in Chemical Engineering from Columbia University and a Master’s in Management Studies from the Sloan School of Management at the Massachusetts Institute of Technology.